share_log

Soleno Therapeutics Stands With the Prader-Willi Syndrome Community

Soleno Therapeutics Stands With the Prader-Willi Syndrome Community

Soleno Therapeutics 與 Prader-Willi綜合症社區站在一起
GlobeNewswire ·  05/15 20:00

This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome community

5月15日是普拉德-威利綜合症宣傳日,與Soleno Therapeutics一起爲Prader-Willi綜合症社區分享希望和善良的信息

REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign aims to raise awareness of PWS and celebrate individuals living with this life-threatening disease.

加利福尼亞州雷德伍德城,2024年5月15日(GLOBE NEWSWIRE)——開發治療罕見疾病的新療法的臨床階段生物製藥公司索理諾治療公司(納斯達克股票代碼:SLNO)(“Soleno” 或 “公司”)今天啓動了一項開創性的計劃,以紀念普拉德-威利綜合症(PWS)宣傳日。該活動旨在提高人們對PWS的認識,並慶祝患有這種危及生命的疾病的人。

PWS is a rare and complex genetic disease affecting approximately one in every 15,000 births globally. Among its characteristics in infants are hypotonia (weak muscles), low muscle mass, and weak suck at birth. As the child develops, the hallmark symptom of potentially life-threatening hyperphagia (insatiable hunger) becomes evident, which can lead to early onset morbid obesity. Other characteristic features of PWS include significant behavioral problems, incomplete sexual development, growth hormone deficiency, and intellectual disability. There is elevated mortality in PWS at all ages.

PWS是一種罕見而複雜的遺傳性疾病,全球每15,000例新生兒中約有一人受到影響。它在嬰兒中的特徵包括肌張力低下(肌肉無力)、肌肉質量低下和出生時吸吮力弱。隨着孩子的發育,可能危及生命的食慾過度(貪得無厭的飢餓)的標誌性症狀變得顯而易見,這可能導致病態肥胖的早期發作。PWS的其他特徵包括嚴重的行爲問題、性發育不完全、生長激素缺乏和智力障礙。所有年齡段的PWS的死亡率都很高。

Soleno's PWS Awareness Month campaign includes a vibrant billboard in New York Times Square featuring nearly 100 individuals from the PWS community, who, along with Soleno Therapeutics, invite others to learn more about PWS and share words of hope, encouragement, and kindness. Through a new website at , the company seeks to foster greater understanding and support for the PWS community.

索理諾的PWS宣傳月活動包括紐約時代廣場上一個充滿活力的廣告牌,其中包括來自PWS社區的近100名個人,他們與Soleno Therapeutics一起邀請其他人進一步了解PWS,分享希望、鼓勵和善良的話語。通過一個新網站,網址爲 ,該公司力求增進對PWS社區的理解和支持。

"At Soleno, we are deeply committed to making a meaningful difference in the lives of individuals with Prader-Willi syndrome," said Dr. Anish Bhatnagar, Chief Executive Officer of Soleno Therapeutics. "This campaign aims to highlight the resilience and beauty within the PWS community, and we hope it will inspire greater awareness, understanding, and support for those living with this rare disease."

Soleno Therapeutics首席執行官阿尼什·巴特納加爾博士表示:“在索理諾,我們堅定地致力於爲普拉德-威利綜合徵患者的生活帶來有意義的改變。”“該活動旨在突出PWS社區內部的韌性和美麗,我們希望它將激發對這種罕見疾病患者的更大認識、理解和支持。”

May is recognized as Prader-Willi Syndrome Awareness Month, supported annually by organizations such as the International Prader-Willi Syndrome Organization (IPWSO), the Foundation for Prader-Willi Research (FPWR) and the Prader-Willi Syndrome Association USA (PWSA USA), and many more organizations around the world. In the United States, May 15th has been designated National Prader-Willi Syndrome Awareness Day, thanks to a joint resolution by United States Congressman Paul D. Tonko (D-NY) and Congresswoman Maria Elvira Salazar (R-FL) in 2023.

五月被認定爲普瑞德-威利綜合症宣傳月,每年都得到國際普拉德威利綜合症組織(IPWSO)、普瑞德威利研究基金會(FPWR)和美國普拉德威利綜合症協會(PWSA USA)等組織以及世界各地更多組織的支持。在美國,5月15日被定爲全國普拉德-威利綜合症宣傳日,這要歸功於美國國會議員保羅·唐科(D-NY)和國會女議員瑪麗亞·埃爾維拉·薩拉查(R-FL)在2023年通過的一項聯合決議。

To learn more about Soleno Therapeutics' commitment to the PWS community and how you can get involved in the campaign, visit .

要詳細了解索理諾療法對PWS社區的承諾以及如何參與該活動,請訪問。

About Soleno Therapeutics, Inc.

關於 Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company's lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program to support a planned NDA submission.

Soleno專注於治療罕見疾病的新療法的開發和商業化。該公司的主要候選藥物DCCR(二氮氧化膽鹼)緩釋片劑,一種用於治療普拉德威利綜合徵(PWS)的每日一次的口服片劑,最近完成了其第三階段開發計劃,以支持計劃提交的保密協議。

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

公司聯繫人:
布萊恩·裏奇
LifeSci 顧問有限公司
212-915-2578


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論